{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:35:48Z","timestamp":1786988148963,"version":"build-2736575974"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ejps.2020.105440","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T20:51:13Z","timestamp":1593463873000},"page":"105440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Biopharmaceutical characterization of rebamipide: The role of mucus binding in regional-dependent intestinal permeability"],"prefix":"10.1016","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3998-1833","authenticated-orcid":false,"given":"Milica","family":"Markovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moran","family":"Zur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3498-3514","authenticated-orcid":false,"given":"Arik","family":"Dahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8291-791X","authenticated-orcid":false,"given":"Sandra","family":"Cviji\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.ejps.2020.105440_bib0001","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0169-409X(01)00179-X","article-title":"Predicting the impact of physiological and biochemical processes on oral drug bioavailability","volume":"50","author":"Agoram","year":"2001","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.ejps.2020.105440_bib0002","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1023\/A:1015347219999","article-title":"Local gastric and serum concentrations of rebamipide following oral ingestion in healthy volunteers","volume":"47","author":"Akamatsu","year":"2002","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejps.2020.105440_bib0003","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."},{"issue":"Suppl 1","key":"10.1016\/j.ejps.2020.105440_bib0004","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s10620-005-2800-9","article-title":"15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications","volume":"50","author":"Arakawa","year":"2005","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejps.2020.105440_bib0005","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1007\/BF02063257","article-title":"Rebamipide, novel prostaglandin-inducer, accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer comparison with cimetidine","volume":"40","author":"Arakawa","year":"1995","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejps.2020.105440_bib0006","doi-asserted-by":"crossref","first-page":"G922","DOI":"10.1152\/ajpgi.2001.280.5.G922","article-title":"The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo","volume":"280","author":"Atuma","year":"2001","journal-title":"Am. J. Physiol.-Gastrointest. Liver Physiol."},{"key":"10.1016\/j.ejps.2020.105440_bib0007","series-title":"Permeability-PAMPA, Absorption and Drug Development","first-page":"319","author":"Avdeef","year":"2012"},{"key":"10.1016\/j.ejps.2020.105440_bib0008","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bcpt.12342","article-title":"Mucus as a barrier to drug delivery - understanding and mimicking the barrier properties","volume":"116","author":"Boegh","year":"2015","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejps.2020.105440_bib0009","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.clinthera.2009.11.010","article-title":"Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers","volume":"31","author":"Cho","year":"2009","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejps.2020.105440_bib0010","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1021\/mp300140h","article-title":"The fraction dose absorbed, in humans, and high jejunal human permeability relationship","volume":"9","author":"Dahan","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2020.105440_bib0011","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/jps.23977","article-title":"Biowaiver monographs for immediate-release solid oral dosage forms: codeine phosphate","volume":"103","author":"Dahan","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105440_bib0012","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1021\/acs.molpharmaceut.6b00514","article-title":"Regional intestinal permeability of three model drugs in human","volume":"13","author":"Dahlgren","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2020.105440_bib0013","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/jps.24258","article-title":"Direct in vivo human intestinal permeability (Peff) determined with different clinical perfusion and intubation methods","volume":"104","author":"Dahlgren","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105440_bib0014","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1208\/s12248-013-9462-x","article-title":"Regional-dependent intestinal permeability and BCS classification: elucidation of pH-related complexity in rats using pseudoephedrine","volume":"15","author":"Fairstein","year":"2013","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2020.105440_bib0015","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1136\/bjophthalmol-2014-305425","article-title":"Inhibition by rebamipide of cytokine-induced or lipopolysaccharide-induced chemokine synthesis in human corneal fibroblasts","volume":"98","author":"Fukuda","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ejps.2020.105440_bib0016","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1002\/jps.24505","article-title":"Few drugs display flip-flop pharmacokinetics and these are primarily associated with classes 3 and 4 of the BDDCS","volume":"104","author":"Garrison","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105440_bib0017","first-page":"223","article-title":"Enhanced bioavailability of rebamipide nanocrystal tablets: formulation and in vitro\/in vivo evaluation","volume":"10","author":"Guo","year":"2015","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105440_bib0018","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5009\/gnl17078","article-title":"Additive effects of rebamipide plus proton pump inhibitors on the expression of tight junction proteins in a rat model of gastro-esophageal reflux disease","volume":"12","author":"Gweon","year":"2018","journal-title":"Gut liver"},{"key":"10.1016\/j.ejps.2020.105440_bib0019","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2165\/00044011-200323120-00002","article-title":"Bioequivalence of rebamipide granules and tablets in healthy adult male volunteers","volume":"23","author":"Hasegawa","year":"2003","journal-title":"Clini. Drug Investig."},{"key":"10.1016\/j.ejps.2020.105440_bib0020","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.3748\/wjg.14.4928","article-title":"Permeabilities of rebamipide via rat intestinal membranes and its colon specific delivery using chitosan capsule as a carrier","volume":"14","author":"Huang","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejps.2020.105440_bib0021","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1007\/s10620-008-0507-4","article-title":"Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test","volume":"54","author":"Iijima","year":"2009","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejps.2020.105440_bib0022","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1021\/mp300410n","article-title":"Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classification","volume":"10","author":"Incecayir","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2020.105440_bib0023","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1007\/s10620-017-4871-9","article-title":"Efficacy of rebamipide in organic and functional dyspepsia: a systematic review and meta-analysis","volume":"63","author":"Jaafar","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejps.2020.105440_bib0024","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/jgh.14021","article-title":"Rebamipide alleviates radiation-induced colitis through improvement of goblet cell differentiation in mice","volume":"33","author":"Jang","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejps.2020.105440_bib0025","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrgastro.2013.35","article-title":"The gastrointestinal mucus system in health and disease","volume":"10","author":"Johansson","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejps.2020.105440_bib0026","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejps.2013.08.025","article-title":"Regional intestinal drug permeation: biopharmaceutics and drug development","volume":"57","author":"Lennernas","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105440_bib0027","first-page":"314","article-title":"[Permeabilities of rebamipide via different intestinal mucosa in the diffusion chamber in vitro]","volume":"43","author":"Li","year":"2008","journal-title":"Yao Xue Xue Bao"},{"key":"10.1016\/j.ejps.2020.105440_bib0028","first-page":"9","article-title":"Predicting oral drug absorption: mini review on physiologically-based pharmacokinetic models","author":"Lin","year":"2017","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2020.105440_bib0029","first-page":"906","article-title":"Development of a simple LC-MS\/MS method for determination of rebamipide in human plasma and its application to a bioequivalence study","volume":"67","author":"Liu","year":"2012","journal-title":"Pharmazie"},{"key":"10.1016\/j.ejps.2020.105440_bib0030","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijpharm.2016.09.061","article-title":"Segmental-dependent permeability throughout the small intestine following oral drug administration: single-pass vs. Doluisio approach to in-situ rat perfusion","volume":"515","author":"Lozoya-Agullo","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2020.105440_bib0031","series-title":"Evaluation of Generic and Brand-Name Rebamipide Tablets by Dissolution Test and Parallel Artificial Membrane Permeability assay","first-page":"223","author":"Maiguma Takayoshi","year":"2013"},{"issue":"3","key":"10.1016\/j.ejps.2020.105440_bib0060","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3390\/pharmaceutics12030295","article-title":"Segmental-dependent solubility and permeability as key factors guiding controlled release drug product development","volume":"12","author":"Markovic","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2020.105440_bib0032","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.3748\/wjg.14.4059","article-title":"Rebamipide enema therapy for left-sided ischemic colitis patients accompanied by ulcers: open label study","volume":"14","author":"Matsumoto","year":"2008","journal-title":"World J. Gastroenterol."},{"issue":"Suppl 1","key":"10.1016\/j.ejps.2020.105440_bib0033","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1365-2036.18.s1.6.x","article-title":"Review article: rebamipide and the digestive epithelial barrier","volume":"18","author":"Matysiak-Budnik","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2020.105440_bib0034","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1016062224568","article-title":"Estimation of the increase in solubility of drugs as a function of bile salt concentration","volume":"13","author":"Mithani","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2020.105440_bib0035","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/00498254.2016.1229085","article-title":"Effect of proinflammatory cytokine IL-6 on efflux transport of rebamipide in Caco-2 cells","volume":"47","author":"Miyake","year":"2017","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejps.2020.105440_bib0036","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s11095-019-2701-9","article-title":"Mucins are Involved in the intestinal permeation of lipophilic drugs in the proximal region of rat small intestine","volume":"36","author":"Miyazaki","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2020.105440_bib0037","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.joca.2012.08.002","article-title":"Rebamipide attenuates pain severity and cartilage degeneration in a rat model of osteoarthritis by downregulating oxidative damage and catabolic activity in chondrocytes","volume":"20","author":"Moon","year":"2012","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.ejps.2020.105440_bib0038","unstructured":"Mucosta\u00ae, Tablets 100 mg leaflet. Otsuka Group Japan. https:\/\/otsuka.pk\/uploads\/files\/Mucosta_Leaflet.pdf. 2000."},{"key":"10.1016\/j.ejps.2020.105440_bib0039","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijpharm.2008.09.027","article-title":"Novel oral absorption system containing polyamines and bile salts enhances drug transport via both transcellular and paracellular pathways across Caco-2 cell monolayers","volume":"367","author":"Mukaizawa","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2020.105440_bib0040","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1023\/A:1018861818023","article-title":"Rebamipide attenuates indomethacin-induced gastric mucosal lesion formation by inhibiting activation of leukocytes in rats","volume":"42","author":"Murakami","year":"1997","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejps.2020.105440_bib0041","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1586\/egh.10.25","article-title":"Rebamipide: a gastrointestinal protective drug with pleiotropic activities","volume":"4","author":"Naito","year":"2010","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejps.2020.105440_bib0042","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10928-017-9519-z","article-title":"Population pharmacokinetic analysis of rebamipide in healthy Korean subjects with the characterization of atypical complex absorption kinetics","volume":"44","author":"Ngo","year":"2017","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2020.105440_bib0043","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3109\/03639045.2012.689765","article-title":"A potent preparation method combining neutralization with microfluidization for rebamipide nanosuspensions and its in vivo evaluation","volume":"39","author":"Shi","year":"2013","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2020.105440_bib0044","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1081\/DDC-200034577","article-title":"Oral absorption and pharmacokinetics of rebamipide and rebamipide lysinate in rats","volume":"30","author":"Shin","year":"2004","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2020.105440_bib0045","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2013.05.040","article-title":"Mucus as a barrier to lipophilic drugs","volume":"453","author":"Sigurdsson","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2020.105440_bib0046","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/jop.2011.0142","article-title":"Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells","volume":"28","author":"Takeji","year":"2012","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2020.105440_bib0047","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/s41598-020-58314-x","article-title":"Rebamipide promotes lacrimal duct epithelial cell survival via protecting barrier function","volume":"10","author":"Tanaka","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejps.2020.105440_bib0048","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1023\/B:DDAS.0000017439.60943.5c","article-title":"Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action?","volume":"49","author":"Tarnawski","year":"2004","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejps.2020.105440_bib0049","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s00535-015-1061-4","article-title":"Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles","volume":"50","author":"Terada","year":"2015","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.ejps.2020.105440_bib0050","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/j.2042-7158.2011.01360.x","article-title":"Formulation of solid dispersion of rebamipide evaluated in a rat model for improved bioavailability and efficacy","volume":"63","author":"Tung","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105440_bib0051","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1007\/s11095-007-9453-7","article-title":"Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter","volume":"24","author":"Uchida","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2020.105440_bib0052","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11095-004-9004-4","article-title":"Predicting drug disposition via application of BCS: transport\/absorption\/ elimination interplay and development of a biopharmaceutics drug disposition classification system","volume":"22","author":"Wu","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2020.105440_bib0053","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.3892\/mmr.2017.7647","article-title":"Rebamipide upregulates mucin secretion of intestinal goblet cells via Akt phosphorylation","volume":"16","author":"Yasuda-Onozawa","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejps.2020.105440_bib0054","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s12885-017-3295-4","article-title":"Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study","volume":"17","author":"Yokota","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejps.2020.105440_bib0055","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s10620-013-2606-0","article-title":"Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis","volume":"58","author":"Zhang","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejps.2020.105440_bib0056","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ijpharm.2015.05.002","article-title":"The biopharmaceutics of successful controlled release drug product: Segmental-dependent permeability of glipizide vs. metoprolol throughout the intestinal tract","volume":"489","author":"Zur","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2020.105440_bib0057","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1021\/mp500152y","article-title":"The low\/high BCS permeability class boundary: physicochemical comparison of metoprolol and labetalol","volume":"11","author":"Zur","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2020.105440_bib0059","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejps.2013.11.007","article-title":"The complexity of intestinal permeability: assigning the correct BCS classification through careful data interpretation","volume":"61","author":"Zur","year":"2014","journal-title":"Eur. J. Pharm. Sci."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098720302293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098720302293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:55:19Z","timestamp":1760529319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098720302293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":59,"alternative-id":["S0928098720302293"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105440","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biopharmaceutical characterization of rebamipide: The role of mucus binding in regional-dependent intestinal permeability","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105440","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105440"}}